# Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients.

> **NCT06223932** · — · UNKNOWN · sponsor: **Serap Yavuz** · enrollment: 2600 (estimated)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection

## Interventions

- **DRUG:** Molnupiravir

## Key facts

- **NCT ID:** NCT06223932
- **Lead sponsor:** Serap Yavuz
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-07
- **Primary completion:** 2024-02
- **Final completion:** 2024-02
- **Target enrollment:** 2600 (ESTIMATED)
- **Last updated:** 2024-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06223932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06223932, "Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients.". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06223932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*